Sector News

Shire and Baxalta near deal

January 4, 2016
Life sciences

Shire is reportedly in advanced talks to acquire Baxter’s biopharma spin-off Baxalta and may announce a deal this week.

According to Bloomberg, sources familiar with the matter have said that the Irish firm could buy Baxalta for $32 billion, or $46.50-$48 a share. The deal is expected to contain a cash component.

After Baxalta’s management rejected an initial bid, Shire went public with a $30 billion unsolicited offer in August 2015, only a month after Baxalta was spun off from Baxter.

After shareholders agreed with the board that this offer was too low, rumours swelled in November that Shire was looking to make a second approach and had asked its advisers to construct a new deal.

Flemming Ornskov, chief executive officer of Shire, has said that the companies could deliver $20 billion in product sales by 2020.

By George Underwood

Source: Pharma Times 

Related News

June 13, 2021

Making drug-resistant bacteria susceptible to antibiotics

Life sciences

Antibiotic resistance remains one of the biggest public health challenges. New drugs are still needed to tackle tough-to-treat bacteria. But finding new therapeutics to kill off pathogenic bacteria has been difficult.

June 13, 2021

Vexed by vectors: How COVID-19 vaccine and cell and gene players are tackling the viral vector bottleneck

Life sciences

Viral vectors are engineered viruses used to deliver gene therapies, gene-modified cell therapies and certain vaccines. And their shortage is already upon us, thanks to manufacturing approaches that simply haven’t kept pace with the advance of cell and gene therapies.

June 13, 2021

Beigene expands into cancer cell therapy with Shoreline pact

Life sciences

Beigene, a fast-growing drugmaker based in Cambridge, Massachusetts and Beijing, will partner with Shoreline Biosciences to develop cell therapies for cancer, expanding its research beyond the small molecule and antibody drugs.

Send this to a friend